Burden of illness of Pompe disease in patients only receiving supportive care
Journal of Inherited Metabolic Disease , Volume 34 - Issue 5 p. 1045- 1052
Background: Pompe disease is an orphan disease for which enzyme replacement therapy (ERT) recently became available. This study aims to estimate all relevant aspects of burden of illness-societal costs, use of home care and informal care, productivity losses, and losses in health-related quality of life (HRQoL)-for adult Pompe patients only receiving supportive care. Methods: We collected data on all relevant aspects of burden of illness via a questionnaire. We applied a societal perspective in calculating costs. The EQ-5D was used to estimate HRQoL. Results: Eighty adult patients (87% of the total Dutch adult Pompe population) completed a questionnaire. Disease severity ranged from mild to severe. Total annual costs were estimated at €22,475 (range €0-169,539) per adult Pompe patient. Patients on average received 8 h of home care and 19 h of informal care per week. Eighty-five percent of the patients received informal care from one or more caregivers; 40% had stopped working due to their disease; another 20% had reduced their working hours. HRQoL for Pompe patients who only received supportive care was estimated at 0.72, 17% lower than the Dutch population at large. Conclusions: Adult Pompe disease is associated with a considerable burden of illness at both the societal and patient levels. The disease leads to substantial costs and dependency on medical devices, home care, and informal care, and has a high impact on the patient's social network. In addition, patients are limited in their ability to work and have significantly reduced HRQoL.
|Journal of Inherited Metabolic Disease|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Kanters, T.A, Hagemans, M.L.C, van der Beek, N.A.M.E, Rutten, F.F.H, van der Ploeg, A.T, & Hakkaart-van Roijen, L. (2011). Burden of illness of Pompe disease in patients only receiving supportive care. Journal of Inherited Metabolic Disease, 34(5), 1045–1052. doi:10.1007/s10545-011-9320-x